{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-003407","form_type":"8-K/A","ticker":"RNAC","cik":"0001453687","company_name":"Cartesian Therapeutics, Inc.","filed_at":"2024-01-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.231424+00:00","generated_at":"2026-06-06T19:57:34.772597+00:00","sec_items":["9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cartesian Therapeutics files financials for acquired Old Cartesian and pro forma","bullets":["Old Cartesian net loss $6.5M in 2022, vs $3.6M in 2021; grant revenue $1.4M in 2022.","Old Cartesian cash $12.0M at Dec 31, 2022; accumulated deficit $26.1M.","Unaudited pro forma financials reflect combined entity post-merger closed Nov 13, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-003407","json":"https://secwatch.observer/filing/0001140361-24-003407.json","markdown":"https://secwatch.observer/filing/0001140361-24-003407.md","text":"https://secwatch.observer/filing/0001140361-24-003407.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1453687/000114036124003407/0001140361-24-003407-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1453687/000114036124003407/ny20014884x4_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T19:57:34.772597+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}